Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Shigeo Koido

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0397-4348; OpenAlex author ID A5003016176. Sources: OpenAlex.

Their work

Papers
25 (first author 5, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
41
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: none · 2014: 4 papers · 2015: 3 papers · 2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: 4 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 25

  1. Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms' tumor 1 (WT1) peptide… Co-author DOI 10.1136/jitc-2024-011426↗
  2. Dendritic cells pulsed with multifunctional Wilms' tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable … Co-author DOI 10.1136/jitc-2024-009765↗
  3. Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12885-021-08911-4↗
  4. Cancerous pericarditis presenting as cardiac tamponade in a 68-year-old man with pancreatic adenocarcinoma: a case report. Last author DOI 10.1186/s13256-020-02546-y↗
  5. Clinical Significance of Tumor-Infiltrating T Cells and Programed Death Ligand-1 in Patients with Pancreatic Cancer. Last author DOI 10.1080/07357907.2019.1661427↗
  6. Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines. Last author DOI 10.1080/21645515.2018.1524238↗
  7. Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1. Last author DOI 10.1159/000500359↗
  8. The Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer. Co-author DOI 10.3390/ijms20133331↗
  9. Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Stud… Co-author DOI 10.1158/2326-6066.cir-17-0386↗
  10. WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study. Co-author DOI 10.21873/anticanres.12464↗
  11. Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.3892/ol.2018.8961↗
  12. Prognostic impact of carbohydrate sulfotransferase 15 in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2017.6071↗
  13. Significance of Wilms' tumor 1 antigen as a cancer vaccine for pancreatic cancer. Co-author PMID 28950074↗
  14. Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer. Co-author DOI 10.2217/imt-2016-0031↗
  15. Comprehensive assessment of the prognosis of pancreatic cancer: peripheral blood neutrophil-lymphocyte ratio and immunohistochemical analyses of the tumour sit… Last author DOI 10.3109/00365521.2015.1121515↗
  16. Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcin… First author DOI 10.1186/s12885-015-1772-1↗
  17. Inhibition of Cell Proliferation and Growth of Pancreatic Cancer by Silencing of Carbohydrate Sulfotransferase 15 In Vitro and in a Xenograft Model. Last author DOI 10.1371/journal.pone.0142981↗
  18. Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for p… First author PMID 25550602↗
  19. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. First author DOI 10.1097/cji.0000000000000020↗
  20. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-0314↗
  21. Long-term management of gemcitabine in a patient with advanced pancreatic cancer undergoing haemodialysis. First author DOI 10.1179/1973947813y.0000000150↗
  22. Chemoimmunotherapy targeting Wilms' tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer. Co-author DOI 10.4161/21624011.2014.958950↗
  23. Immunotherapy synergizes with chemotherapy targeting pancreatic cancer. Co-author DOI 10.2217/imt.11.150↗
  24. Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. First author DOI 10.1007/s00262-011-1033-3↗
  25. Current immunotherapeutic approaches in pancreatic cancer. Co-author DOI 10.1155/2011/267539↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Haruo Sugiyama · 16 shared papers, 2011–2025 · strength 1.31
  2. Zensho Ito · 11 shared papers, 2015–2025 · strength 1.03
  3. Masayuki Saruta · 8 shared papers, 2018–2025 · strength 0.95
  4. Shigetaka Shimodaira · 8 shared papers, 2014–2025 · strength 0.81
  5. Masato Okamoto · 12 shared papers, 2014–2019 · strength 0.80
  6. Toshifumi Ohkusa · 5 shared papers, 2017–2025 · strength 0.63
  7. Shin Kan · 7 shared papers, 2014–2024 · strength 0.56
  8. Kazuki Takakura · 9 shared papers, 2014–2019 · strength 0.49
  9. Mikio Kajihara · 8 shared papers, 2014–2019 · strength 0.41
  10. Masamori Shimabuku · 2 shared papers, 2024–2025 · strength 0.38
  11. Sadamu Homma · 10 shared papers, 2011–2018 · strength 0.37
  12. Shuichi Fujioka · 4 shared papers, 2017–2021 · strength 0.32
  13. Shintaro Tsukinaga · 4 shared papers, 2011–2024 · strength 0.26
  14. Hisao Tajiri · 8 shared papers, 2011–2015 · strength 0.25
  15. Sachie Kiryu · 2 shared papers, 2020–2021 · strength 0.23
  16. Tomoya Kanai · 3 shared papers, 2016–2018 · strength 0.18
  17. Sumiyuki Nishida · 4 shared papers, 2011–2018 · strength 0.17
  18. Sayumi Yoshida · 2 shared papers, 2019 · strength 0.16
  19. Akitaka Takahara · 5 shared papers, 2011–2014 · strength 0.14
  20. Shuichi Hanada · 1 shared paper, 2019 · strength 0.11
  21. Yuichi Torisu · 1 shared paper, 2019 · strength 0.11
  22. Naohisa Yahagi · 1 shared paper, 2019 · strength 0.11
  23. Hidetoshi Eguchi · 2 shared papers, 2014–2018 · strength 0.09
  24. Hiroaki Nagano · 2 shared papers, 2014–2018 · strength 0.09
  25. Ryu Yanagisawa · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.